IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
A salient feature of pancreatic ductal adenocarcinoma (PDAC) is an abundant fibroinflammatory response characterized by the recruitment of immune and mesenchymal cells and the consequent establishment of a protumorigenic microenvironment. Here, we report the prominent presence of B cells in human pancreatic intraepithelial neoplasia and PDAC lesions as well as in oncogenic Kras-driven pancreatic neoplasms in the mouse. The growth of orthotopic pancreatic neoplasms harboring oncogenic Kras was significantly compromised in B-cell–deficient mice (μMT), and this growth deficiency could be rescued by the reconstitution of a CD1dhiCD5+ B-cell subset. The protumorigenic effect of B cells was mediated by their expression of IL35 through a mechanism involving IL35-mediated stimulation of tumor cell proliferation. Our results identify a previously unrecognized role for IL35-producing CD1dhiCD5+ B cells in the pathogenesis of pancreatic cancer and underscore the potential significance of a B-cell/IL35 axis as a therapeutic target. Significance: This study identifies a B-cell subpopulation that accumulates in the pancreatic parenchyma during early neoplasia and is required to support tumor cell growth. Our findings provide a rationale for exploring B-cell–based targeting approaches for the treatment of pancreatic cancer. Cancer Discov; 6(3); 247–55. ©2015 AACR. See related commentary by Roghanian et al., p. 230. See related article by Lee et al., p. 256. See related article by Gunderson et al., p. 270. This article is highlighted in the In This Issue feature, p. 217
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Shen, P., Roch, T., Lampropoulou, V., O’Connor, R. A., Stervbo, U., Hilgenberg, E., Ries, S., Dang, V. D., Jaimes, Y., Daridon, C., et al. (2014) · Nature · doi:10.1038/nature12979 · Cited by 1,048 · cited 1×
“In a model of experimental autoimmune encephalomyelitis (EAE), activation of TLR4 and CD40 has been shown to induce the upregulation of mRNAs encoding subunits of IL-35 (IL12a and Ebi3) by B cells(25).”
BackgroundBayne, L. J., Beatty, G. L., Jhala, N., Clark, C. E., Rhim, A. D., Stanger, B. Z., & Vonderheide, R. H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.025 · Cited by 947 · cited 1×
“For example, tumor associated macrophages and myeloid-derived suppressor cells have been shown to promote pancreatic tumorigenesis through the suppression of antitumor immunity via expression of heme oxygenase-1 and arginase, respectively (2-4).”
BackgroundLesina, M., Kurkowski, M. U., Ludes, K., Rose-John, S., Treiber, M., Klöppel, G., Yoshimura, A., Reindl, W., Sipos, B., Akira, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.009 · Cited by 862
Interleukin-35 induces regulatory B cells that suppress autoimmune disease
Wang, R.-X., Yu, C.-R., Dambuza, I. M., Mahdi, R. M., Dolinska, M. B., Sergeev, Y. V., Wingfield, P. T., Kim, S.-H., & Egwuagu, C. E. (2014) · Nature Medicine · doi:10.1038/nm.3554 · Cited by 733
Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia
Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G., & Bar-Sagi, D. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.024 · Cited by 721 · cited 7×
“The LSL-Kras, Pdx1-Cre and p48-Cre strains have been described previously(3).”
BackgroundMethodInfluentialSelf-citationB-cell-derived lymphotoxin promotes castration-resistant prostate cancer
Ammirante, M., Luo, J.-L., Grivennikov, S., Nedospasov, S., & Karin, M. (2010) · Nature · doi:10.1038/nature08782 · Cited by 639
FcRγ Activation Regulates Inflammation-Associated Squamous Carcinogenesis
Andreu, P., Johansson, M., Affara, N. I., Pucci, F., Tan, T., Junankar, S., Korets, L., Lam, J., Tawfik, D., DeNardo, D. G., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.019 · Cited by 590
Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer
Gunderson, A. J., Kaneda, M. M., Tsujikawa, T., Nguyen, A. V., Affara, N. I., Ruffell, B., Gorjestani, S., Liudahl, S. M., Truitt, M., Olson, P., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0827 · Cited by 486
The composition and signaling of the IL-35 receptor are unconventional
Collison, L. W., Delgoffe, G. M., Guy, C. S., Vignali, K. M., Chaturvedi, V., Fairweather, D., Satoskar, A. R., Garcia, K. C., Hunter, C. A., Drake, C. G., et al. (2012) · Nature Immunology · doi:10.1038/ni.2227 · Cited by 450
Cited by
Inflammation and cancer: triggers, mechanisms, and consequences
Greten, F. R., & Grivennikov, S. I. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.025 · Cited by 3,806
“B cells recruited into tumors regulate anti-cancer immune responses, exert direct tumor promoting roles or modulate myeloid cell response, all of that dictated by the signals B cells received from TME and by the nature of ligands their BCR’s recognize (Ammirante et al., 2014; Das and Bar-Sagi, 2019; Medler et al., 201…”
BackgroundRoles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
Anderson, K. G., Stromnes, I. M., & Greenberg, P. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.008 · Cited by 702
B cells, plasma cells and antibody repertoires in the tumour microenvironment
Sharonov, G. V., Serebrovskaya, E. O., Yuzhakova, D. V., Britanova, O. V., & Chudakov, D. M. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0257-x · Cited by 627
A history of exploring cancer in context
Maman, S., & Witz, I. P. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0006-7 · Cited by 502
Genetics and biology of pancreatic ductal adenocarcinoma
Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes & Development · doi:10.1101/gad.275776.115 · Cited by 527
Orth, M., Metzger, P., Gerum, S., Mayerle, J., Schneider, G., Belka, C., Schnurr, M., & Lauber, K. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1345-6 · Cited by 490
Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer
Gunderson, A. J., Kaneda, M. M., Tsujikawa, T., Nguyen, A. V., Affara, N. I., Ruffell, B., Gorjestani, S., Liudahl, S. M., Truitt, M., Olson, P., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0827 · Cited by 486
Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance
Sherman, M. H., & Beatty, G. L. (2023) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031621-024600 · Cited by 467
Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer
Hegde, S., Krisnawan, V. E., Herzog, B. H., Zuo, C., Breden, M. A., Knolhoff, B. L., Hogg, G. D., Tang, J. P., Baer, J. M., Mpoy, C., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.02.008 · Cited by 463
Immunotherapy for pancreatic cancer: A 2020 update
Schizas, D., Charalampakis, N., Kole, C., Economopoulou, P., Koustas, E., Gkotsis, E., Ziogas, D., Psyrri, A., & Karamouzis, M. V. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102016 · Cited by 458
Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities
Balachandran, V. P., Beatty, G. L., & Dougan, S. K. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.038 · Cited by 444
Targeting B cell receptor signalling in cancer: preclinical and clinical advances
Burger, J. A., & Wiestner, A. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.121 · Cited by 431
Immunosuppressive Mechanisms of Regulatory B Cells
Catalán, D., Mansilla, M. A., Ferrier, A., Soto, L., Oleinika, K., Aguillón, J. C., & Aravena, O. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.611795 · Cited by 399
Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer
Halbrook, C. J., & Lyssiotis, C. A. (2017) · Cancer Cell · doi:10.1016/j.ccell.2016.12.006 · Cited by 393
Bernard, V., Semaan, A., Huang, J., San Lucas, F. A., Mulu, F. C., Stephens, B. M., Guerrero, P. A., Huang, Y., Zhao, J., Kamyabi, N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1955 · Cited by 389
Tumor Cell–Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer
Das, S., Shapiro, B., Vucic, E. A., Vogt, S., & Bar-Sagi, D. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2080 · Cited by 366
Self-citationCXCL13 and Its Receptor CXCR5 in Cancer: Inflammation, Immune Response, and Beyond
Kazanietz, M. G., Durando, M., & Cooke, M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00471 · Cited by 356
Xiao, X., Lao, X.-M., Chen, M.-M., Liu, R.-X., Wei, Y., Ouyang, F.-Z., Chen, D.-P., Zhao, X.-Y., Zhao, Q., Li, X.-F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1408 · Cited by 352
STING-induced regulatory B cells compromise NK function in cancer immunity
Li, S., Mirlekar, B., Johnson, B. M., Brickey, W. J., Wrobel, J. A., Yang, N., Song, D., Entwistle, S., Tan, X., Deng, M., et al. (2022) · Nature · doi:10.1038/s41586-022-05254-3 · Cited by 347
Self-citationThe Emerging Role of B Cells in Tumor Immunity
Tsou, P., Katayama, H., Ostrin, E. J., & Hanash, S. M. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0431 · Cited by 345
Bruno, T. C., Ebner, P. J., Moore, B. L., Squalls, O. G., Waugh, K. A., Eruslanov, E. B., Singhal, S., Mitchell, J. D., Franklin, W. A., Merrick, D. T., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0075 · Cited by 301
Ye, L., Zhang, Q., Cheng, Y., Chen, X., Wang, G., Shi, M., Zhang, T., Cao, Y., Pan, H., Zhang, L., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0451-6 · Cited by 293
B Cell Function in the Tumor Microenvironment
Downs-Canner, S. M., Meier, J., Vincent, B. G., & Serody, J. S. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101220-015603 · Cited by 287
Emerging immunotherapy for HCC: A guide for hepatologists
Foerster, F., Gairing, S. J., Ilyas, S. I., & Galle, P. R. (2022) · Hepatology · doi:10.1002/hep.32447 · Cited by 240
Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment
Kerk, S. A., Papagiannakopoulos, T., Shah, Y. M., & Lyssiotis, C. A. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00375-9 · Cited by 237
The pancreatic cancer genome revisited
Hayashi, A., Hong, J., & Iacobuzio-Donahue, C. A. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00463-z · Cited by 211
Hessmann, E., Patzak, M. S., Klein, L., Chen, N., Kari, V, Ramu, I., Bapiro, T. E., Frese, K. K., Gopinathan, A., Richards, F. M., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-311954 · Cited by 202
Tumor-associated B-cells induce tumor heterogeneity and therapy resistance
Somasundaram, R., Zhang, G., Fukunaga-Kalabis, M., Perego, M., Krepler, C., Xu, X., Wagner, C., Hristova, D., Zhang, J., Tian, T., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00452-4 · Cited by 151
Cytokine and Chemokine Signals of T‐Cell Exclusion in Tumors
Zhang, Y., Guan, X.-Y., & Jiang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594609 · Cited by 133
Lee, J. J., Bernard, V., Semaan, A., Monberg, M. E., Huang, J., Stephens, B. M., Lin, D., Rajapakshe, K. I., Weston, B. R., Bhutani, M. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3925 · Cited by 128
Barriga, F. M., Tsanov, K. M., Ho, Y.-J., Sohail, N., Zhang, A., Baslan, T., Wuest, A. N., Del Priore, I., Meškauskaitė, B., Livshits, G., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00443-5 · Cited by 125
Self-citationCombined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
Tang, K. H., Li, S., Khodadadi-Jamayran, A., Jen, J., Han, H., Guidry, K., Chen, T., Hao, Y., Fedele, C., Zebala, J. A., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0369 · Cited by 105
Truong, L.-H., & Pauklin, S. (2021) · Cancers · doi:10.3390/cancers13195028 · Cited by 102
Kras and tumor immunity: friend or foe?
Cullis, J., Das, S., & Bar-Sagi, D. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031849 · Cited by 85
“B cells constitute a significant proportion of lymphocytes in both early and late stages of pancreatic cancer (Gunderson et al. 2016; Pylayeva-Gupta et al. 2016), with a somewhat contradictory role in tumorigenesis.”
BackgroundSelf-citationMota Reyes, C., Teller, S., Muckenhuber, A., Konukiewitz, B., Safak, O., Weichert, W., Friess, H., Ceyhan, G. O., & Demir, I. E. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1864 · Cited by 80
Metadata
- Authors
- Pylayeva-Gupta, Y., Das, S., Handler, J. S., Hajdu, C. H., Coffre, M., Koralov, S. B., & Bar-Sagi, D.
- Venue
- Cancer Discovery
- Published
- 2016-03-01
- Volume
- 6
- Issue
- 3
- Pages
- 247-255
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2200842302
- Cited by
- 357
- References
- 30
- FWCI
- 9.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.